Leucine-Rich Alpha-2 Glycoprotein Is a Potential Biomarker to Monitor Disease Activity in IBD Patients Receiving Adalimumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Biomarker to Monitor Disease Activity in Inflammatory Bowel Disease Receiving Adalimumab: PLANET Study
J. Gastroenterol. 2021 May 03;[EPub Ahead of Print], S Shinzaki, K Matsuoka, H Tanaka, F Takeshima, S Kato, T Torisu, Y Ohta, K Watanabe, S Nakamura, N Yoshimura, T Kobayashi, A Shiotani, F Hirai, S Hiraoka, M Watanabe, M Matsuura, S Nishimoto, S Mizuno, H Iijima, T Takehara, T Naka, T Kanai, T MatsumotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.